The present invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein m represents 1, n represents 1, Z represents N or C, in particular N； &mdash；X1&mdash； represents C1-4alkyl, in particular methyl； &mdash；X2&mdash； represents &mdash；C1-4alkyl- or &mdash；C1-4alkyl-NR7&mdash；, in particular propyl, -ethyl-NR7&mdash； or -propyl-NR7&mdash；； &mdash；Y&mdash； represents &mdash；NR2&mdash；C1-6alkyl-CO&mdash；NR4&mdash；, -Het1-C1-6alkyl-CO&mdash；NR5&mdash； or -Het2-CO&mdash；NR6&mdash； and wherein the &mdash；C1-6alkyl-linker of &mdash；NR2&mdash；C1-6alkyl-CO&mdash；NR4&mdash； or -Het1-C1-6alkyl-CO&mdash；NR5&mdash； is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo and phenyl； R1 represents hydrogen, chloro, fluoro or bromo； R2 represents &mdash；C1-4alkyl-, in particular ethyl or methyl； R7 represents hydrogen； R8 represents hydrogen； R4, R5 and R6 represent hydrogen； Het1 is selected from piperazinyl or piperidinyl, in particular -piperazinyl； Het2 selected from pyrrolidinyl or piperidinyl, in particular pyrrolidinyl wherein said pyrrolidinyl is optionally substituted with hydroxy.
